SCHEMBL3754279

SCHEMBL3754279

CCn1nc(C)cc1NC=C(C(=O)O)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.50
LMNA P02545 3/20 0.49
STAT1 P42224 1/20 0.49
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44
NPY1R P25929 1/20 0.44
NPY2R P49146 1/20 0.44
KMT2A Q03164 1/20 0.44
MAPT P10636 3/20 0.41
APAF1 O14727 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 1/20 0.37
SMYD3 Q9H7B4 1/20 0.37
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL583369 0.85 GAA (0.70) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL11716091 0.84 GAA (0.46) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL20413728 0.81 GAA (0.50) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL3600779 0.80 SMN1; SMN2 (0.53) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL10330271 0.78 GAA (0.53) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL3606132 0.75 SMN1; SMN2 (0.39) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL7095365 0.74 LMNA (0.73) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL11627998 0.74 GAA (0.42) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL17963146 0.74 GAA (0.67) GAALMNASTAT1NPSR1SMN1; SMN2
SCHEMBL25825666 0.73 GAA (0.51) GAALMNANPSR1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed
EP-2124944-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-12-02 EP disclosed
EP-2124943-A1 PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2009-12-02 EP disclosed
WO-2008111010-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-09-18 WO disclosed
WO-2008111009-A1 PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A GAA 739/4885LMNA 4852/4885STAT1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.